Embo Medical, an early stage medical device company focused on developing technology to shut down blood flow in blood vessels, has secured €3 million in seed-funding.
The company will research embolisation, a minimally invasive endovascular procedure used to deliberately stop blood flow in blood vessels when treating cancers, internal haemorrhage, aneurysms, and venous disease. Current embolisation procedures require multiple coils and plugs, which can be cumbersome and time consuming to insert.
Embo is developing the first true one-shot (one device per vessel) vascular embolisation device. The product is aimed at the peripheral vascular embolisation market, a market where physicians perform about 180,000 procedures per year worldwide. The Embo platform technology is intended to provide shorter procedural times; resulting in safe, cost-effective embolisation. In preclinical studies, Embo’s technology reduced blood vessel treatment time by over 80%, while ensuring rapid and durable occlusion across all blood vessel sizes.
Embo CEO Wayne Allen said: “This investment will accelerate Embo’s development of a state-of-the-art solution for the treatment of several diseases, will further prove the product’s value through clinical studies and enable us to access the large US market. Our technology has the potential to become the standard of care while simultaneously reducing the cost of healthcare.”
Dr Mahmood K. Razavi, Interventional Radiologist and Director of Clinical Trials, St. Joseph Heart & Vascular Centre, Orange, CA, USA, said: “The innovative Embo solution combines the desirable characteristics of coils and plugs into one device and represents a potential new gold standard in embolisation. It is designed for safe and easy delivery, and rapid cessation of blood flow. The technology will be a clinically effective approach for patients requiring embolisation.”